Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colistimethate sodium inhaled - Zambon

Next Previous
X
Search
Drug Profile

Colistimethate sodium inhaled - Zambon

Alternative Names: Inhaled colistimethate sodium - Zambon; Promixin; ZP 044

Latest Information Update: 27 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profile Pharma
  • Developer Zambon SpA
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase III Pseudomonal infections

Most Recent Events

  • 18 Jul 2023 Zambon terminates a phase III PROMIS II trial in Pseudomonal infections in USA, Argentina, Canada, France, New Zealand, Poland, Portugal, Germany, Greece, Australia, Israel and Italy (Inhalation, Liquid) due to both the COVID-19 pandemic and the view of investigators (EudraCT2016-004558-13) (NCT03460704)
  • 18 Jul 2023 Efficacy and safety data from the phase III PROMIS II trial in Pseudomonal infections released by Zambon SpA
  • 23 Feb 2023 Colistimethate sodium inhaled is still in phase III development for in Pseudomonal infections Australia, Belgium, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Portugal, Spain, Switzerland, United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top